Home / Oncology Nursing / You are invited to attend a program by Taiho Oncology, Inc., on patient management and education of LONSURF (trifluridine and tipiracil) tablets

You are invited to attend a program by Taiho Oncology, Inc., on patient management and education of LONSURF (trifluridine and tipiracil) tablets

You are invited to attend a program by Taiho Oncology, Inc., on patient management and education of LONSURF (trifluridine and tipiracil) tablets for previously treated metastatic colorectal, gastric and gastroesophageal (GEJ) cancers.

NOTE: Pursuant to the PhRMA Code on Interactions with Healthcare Professionals, as well as the policies of Taiho Oncology, Inc., attendance of this promotional program is restricted to healthcare professionals (HCPs) within the targeted oncology specialty. Accordingly, spouses and guests are not permitted to attend this program unless they are an HCP within the targeted oncology specialty.

Taiho will report information related to the event, such as your name and the value and purpose of any educational item, meal or other items of value you receive, to the extent required by federal and state laws, as applicable.  Please let us know if you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or government entity that limits or prohibits meals from pharmaceutical companies.  HCPs may attend the program and decline a meal.  Please note this with your registration and designate this at the venue as you sign-in for the program.

Indication

LONSURF is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Selected Important Safety Information

Severe Myelosuppression: LONSURF caused severe and life‑threatening myelosuppression (Grade 3‑4) consisting of neutropenia (38%), anemia (18%),  thrombocytopenia (5%), and febrile neutropenia (3%). Two patients (0.2%) died due to neutropenic infection. A total of 12% of LONSURF‑treated patients received granulocyte‑colony stimulating factors. Obtain complete blood counts prior to and on day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for febrile neutropenia, absolute neutrophil count less than 500/mm3, or platelets less than 50,000/mm3. Upon recovery, resume LONSURF at a reduced dose as clinically indicated.

Embryo-Fetal Toxicity: LONSURF can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 6 months after the final dose.

Wednesday, October 16, 2019

Los Angeles, CA

Time: 6:00 PM – 8:30 PM

Location: The Palm Restaurant

1100 South Flower Street

Los Angeles, CA 90015

Presented by:

Megan Price, APRN, MSN, FNP-C

UCLA Hematology Oncology

Santa Monica, CA

Tuesday, October 22, 2019

Weston, WI

Time: 6:00 PM – 8:30 PM

Location: Wish Steakhouse

5006 E Jelinek Avenue

Weston, WI 54476

Presented by:

Latha Radhakrishnan, PharmD, BCPS, BCOP

The University of Illinois at Chicago

Chicago, IL

Tuesday, November 19, 2019

Hackensack, NJ

Time: 6:00 PM – 8:00 PM

Location: The Oceanaire Seafood Room175

Riverside Square Mall

Hackensack, NJ 07601

Presented by:

Megan Price, APRN, MSN, FNP-CUCLA

Hematology Oncology

Santa Monica, CA

Important Safety Information

WARNINGS AND PRECAUTIONS

Severe Myelosuppression:

LONSURF caused severe and life‑threatening myelosuppression (Grade 3‑4) consisting of neutropenia (38%), anemia (18%), thrombocytopenia (5%), and febrile neutropenia (3%). Two patients (0.2%) died due to neutropenic infection. A total of 12% of LONSURF‑treated patients received granulocyte‑colony stimulating factors. Obtain complete blood counts prior to and on day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for febrile neutropenia, absolute neutrophil count less than 500/mm3, or platelets less than 50,000/mm3. Upon recovery, resume LONSURF at a reduced dose as clinically indicated.

Embryo‑Fetal Toxicity:

LONSURF can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 6 months after the final dose.

USE IN SPECIFIC POPULATIONS

Lactation: It is not known whether LONSURF or its metabolites are present in human milk. There are no data to assess the effects of LONSURF or its metabolites on the breast‑fed infant or the effects on milk production. Because of the potential for serious adverse reactions in breast‑fed infants, advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose.

Male Contraception: Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use condoms during treatment with LONSURF and for at least 3 months after the final dose.

Geriatric Use: Patients 65 years of age or over who received LONSURF had a higher incidence of the following compared to patients younger than 65 years: Grade 3 or 4 neutropenia (46% vs 32%), Grade 3 anemia (22% vs 16%), and Grade 3 or 4 thrombocytopenia (7% vs 4%).

Hepatic Impairment: Do not initiate LONSURF in patients with baseline moderate or severe (total bilirubin greater than 1.5 times ULN and any AST) hepatic impairment. Patients with severe hepatic impairment (total bilirubin greater than 3 times ULN and any AST) were not studied. No adjustment to the starting dose of LONSURF is recommended for patients with mild hepatic impairment.

Renal Impairment: No adjustment to the starting dosage of LONSURF is recommended in patients with mild or moderate renal impairment (CLcr of 30 to 89 mL/min). Patients with severe renal impairment (CLcr < 30 mL/min) were not studied.

ADVERSE REACTIONS

Most Common Adverse Drug Reactions in Patients Treated With LONSURF (≥5%): The most common adverse drug reactions in LONSURF‑treated patients vs placebo‑treated patients with mCRC, respectively, were asthenia/fatigue (52% vs 35%), nausea (48% vs 24%), decreased appetite (39% vs 29%), diarrhea (32% vs 12%), vomiting (28% vs 14%), infections (27% vs 16%), abdominal pain (21% vs 18%), pyrexia (19% vs 14%), stomatitis (8% vs 6%), dysgeusia (7% vs 2%), and alopecia (7% vs 1%). In metastatic gastric cancer or gastroesophageal junction (GEJ), the most common adverse drug reactions, respectively were, nausea (37% vs 32%), decreased appetite (34% vs 31%), vomiting (25% vs 20%), infections (23% vs 16%) and diarrhea (23% vs 14%).

Pulmonary emboli occurred more frequently in LONSURF‑treated patients compared to placebo: (2% vs 0%) in mCRC and (3% vs 2%) in metastatic gastric cancer and GEJ.

Interstitial lung disease (0.2%), including fatalities, has been reported in clinical studies and clinical practice settings in Asia.

Laboratory Test Abnormalities in Patients Treated With LONSURF: Laboratory test abnormalities in LONSURF‑treated patients vs placebo-treated patients with mCRC, respectively, were anemia (77% vs 33%), neutropenia (67% vs 1%), and thrombocytopenia (42% vs 8%).  In metastatic gastric cancer or GEJ, the test abnormalities, respectively, were neutropenia (66% vs 4%), anemia (63% vs 38%), and thrombocytopenia (34% vs 9%).

Please see full Prescribing Information

 

Click here for full Prescribing Information

 

© TAIHO ONCOLOGY, INC.  03/2019  All rights reserved. LON-PM-US-0831

Lonsurf is a registered trademark of Taiho Pharmaceutical Co. Ltd. used under license by Taiho Oncology, Inc.